Trastuzumab Deruxtecan in Previously Treated HER2-Low

trastuzumab  Trastuzumab exerts an antitumour activity and is used in the treatment of HER2-positive breast cancer HER2 protein overexpression is observed in 20%-30% of If you're having trastuzumab to treat primary breast cancer after surgery, it's usually given for 1 year Some people may be offered

On April 5, 2024, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Trastuzumab deruxtecan may cause hair loss Any hair loss caused should be temporary and in most cases your hair will begin to grow back once your treatment has

Trastuzumab is a monoclonal antibody targeted against the HER2 tyrosine kinase receptor The majority of patients with metastatic breast Trastuzumab deruxtecan Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal